Benzinga | Mar 29, 2021 09:03AM EDT

AIkido Pharma Sponsors Psychedelic Compound Research to Treat PTSD

AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced that it is sponsoring psychedelic research at the Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research (theAIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced that it is sponsoring psychedelic research at the Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research (the "Center"). The Center examines the therapeutic potential of psychedelic compounds for post-traumatic stress disorder (PTSD) and other trauma-related symptoms.